cleancap egfp mrna (TriLink)
90
Structured Review
TriLink
cleancap egfp mrna
Cleancap Egfp Mrna, supplied by TriLink, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleancap+egfp-mrna/cleancap+egfp+mrna/pmc12221739-155-0-20
Average 90 stars, based on 1 article reviews
Cleancap Egfp Mrna, supplied by TriLink, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cleancap+egfp-mrna/cleancap+egfp+mrna/pmc12221739-155-0-20
Average 90 stars, based on 1 article reviews
cleancap egfp mrna - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "mRNA-based in vivo induction of ETV2 to restore blood flow in a preclinical mouse hindlimb ischemia model"
Article Title: mRNA-based in vivo induction of ETV2 to restore blood flow in a preclinical mouse hindlimb ischemia model
Journal: Molecular Therapy. Nucleic Acids
doi: 10.1016/j.omtn.2025.102592
Figure Legend Snippet: Synthetic mRNA encoding ETV2 is efficiently translated into functional protein in vitro (A) EGFP or ETV2 protein expression at 15 h after mRNA transfection with MessengerMAX. Representative blight filed image and fluorescence image. Scale bars, 75 μm. TF, transfection reagent. (B) After mRNA transfection with MessengerMAX, the cells were collected at 24, 48, or 72 h time point. Total RNA extraction, cDNA synthesis, and qPCR analysis by ΔΔCT method were conducted. For each condition, n = 4; mean ± SD. ∗∗ p < 0.01 by two-way ANOVA with Bonferroni correction. (C) CDH5 protein expression at 24, 48, and 72 h time points after mRNA transfection were analyzed by western Blotting. The number above each gel lane represent the fold-change in intensity relative to control (TF only, 24 h).
Techniques Used: Functional Assay, In Vitro, Expressing, Transfection, Fluorescence, RNA Extraction, cDNA Synthesis, Western Blot, Control
Figure Legend Snippet: In vivo biodistribution of the injected ETV2 mRNA with LNP and protein expression in skeletal muscle (A) ETV2 mRNA visualization with RNAscope. Quadriceps were collected 5 h after LNP (0.5 μg/limb) administration intramuscularly. Longitudinal section of the whole quadriceps was analyzed. Scare bars, 3 mm (low-magnification). (B and C) Representative images of (B) ETV2 mRNA visualization with RNAscope and (C) ETV2 protein visualization with IHC. Scale bars, 100 μm (high-magnification).
Techniques Used: In Vivo, Injection, Expressing, RNAscope
Figure Legend Snippet: Profiling the cellular functional distribution of intramuscularly administrated mRNA/LNP (A) Schematic of the Ai6 transgenic mouse LoxP-flanked stop cassette preventing the transcription of ZsGreen. Upon delivery of Cre recombinase via Cre mRNA, the stop cassette is excised, and the cell expresses ZsGreen. (B) Experimental design of the functional delivery assay in vivo . (C) Gating strategy for each cell population: leukocytes, endothelial cells (ECs), and fibro/adipogenic progenitors (FAPs). (D) Flow cytometry scatter plots of ZsGreen expression in each cell population in PBS or Cre mRNA injected Ai6 mice. (E) ZsGreen expression in each cell population ( n = 2 mice). Data are represented as mean ± SD. ∗∗ p < 0.01.
Techniques Used: Functional Assay, Transgenic Assay, In Vivo, Flow Cytometry, Expressing, Injection
Figure Legend Snippet: LNP encapsulating ETV2 mRNA promotes blood flow supply in a hindlimb ischemia model using BALB/c athymic mice (A) Experimental design of HLI study. On day 0 post the HLI surgery, PBS or LNP (3 μg/limb) was administered intramuscularly once a week up to 4 weeks. ETV2 lentivirus was administered intramuscularly on day 0 post HLI surgery. Blood flow was analyzed by LDI by day 35. (B) Representative LDI images on day 0 pre/post HLI surgery and day 14 post HLI surgery. (C) The ratio of blood flow (left injured limb/right normal limb) at all time points for all groups was shown. For each group, n = 6–15; mean ± SE. (D) The ratio of blood flow (left injured limb/right normal limb) at day 14 and day 28 was shown. ∗ p < 0.5 and ∗∗ p < 0.01 by two-way ANOVA with Bonferroni correction.
Techniques Used:
Related Articles
Expressing:Article Title: Expression of a RAS Degrader via Synthetic Nanocarrier-Mediated mRNA Delivery Reduces Pancreatic Tumors. Article Snippet: Therapeutic gene expression can address many of the challenges associated with the controlled delivery of intracellularly active biologics, such as enzymes that degrade RAS for the treatment of RAS-driven cancers.. Here, we demonstrate that an optimized synthetic nonviral gene delivery platform composed of poly(ethylene glycol)-b-poly(propylene sulfide) (PEG−PPS) can block copolymers conjugated to a dendritic cationic peptide (PPDP2) for nontoxic delivery and therapeutic expression of mRNA within human pancreatic cancer cells and tumors.. The naturally occurring bacterial enzyme RAS/RAP1-specific endopeptidase (RRSP) is a potent RAS degrader that specifically targets all RAS isoforms. Article Title: Don't shake it! Mechanical stress testing of mRNA-lipid nanoparticles. Article Snippet: PolyA (ABP Biosciences, Virginia, USA) or Article Title: TECPR1 is activated by damage-induced sphingomyelin exposure to mediate noncanonical autophagy. Article Snippet: Other reagents used were 10k MWCO Slide-A-Lyzer G2 cassette (ThermoFisher Scientific, 87730), Adenosine-50-triphosphate (Sigma-Aldrich, A2383) (ATP), Amicon Ultra 30K centrifugal filter (Millipore, UFC803096), Ammonium chloride (NH4Cl), anti-Flag M2 affinity gel (Sigma-Aldrich, A2220), Any kD Mini-PROTEAN TGX Precast Protein Gels 15-well (for coomassie stains) Bio-Rad, 4569036, astemizole (Sigma-Aldrich, A2861), bafilomycin A1 (AH diagnostics, BML-CM110) (BafA1), BalanCD HEK293 Feed (Irvine Scientific, 91166), BalanCD HEK293 Liquid (Irvine Scientific, 91165), blasticidine S (InvivoGen, ant-bl-1), Citrate Buffer pH 3.0 (TekNova, Q2445), Negative Control:Article Title: Expression of a RAS Degrader via Synthetic Nanocarrier-Mediated mRNA Delivery Reduces Pancreatic Tumors. Article Snippet: Therapeutic gene expression can address many of the challenges associated with the controlled delivery of intracellularly active biologics, such as enzymes that degrade RAS for the treatment of RAS-driven cancers.. Here, we demonstrate that an optimized synthetic nonviral gene delivery platform composed of poly(ethylene glycol)-b-poly(propylene sulfide) (PEG−PPS) can block copolymers conjugated to a dendritic cationic peptide (PPDP2) for nontoxic delivery and therapeutic expression of mRNA within human pancreatic cancer cells and tumors.. The naturally occurring bacterial enzyme RAS/RAP1-specific endopeptidase (RRSP) is a potent RAS degrader that specifically targets all RAS isoforms. Article Title: Don't shake it! Mechanical stress testing of mRNA-lipid nanoparticles. Article Snippet: PolyA (ABP Biosciences, Virginia, USA) or Article Title: TECPR1 is activated by damage-induced sphingomyelin exposure to mediate noncanonical autophagy. Article Snippet: Other reagents used were 10k MWCO Slide-A-Lyzer G2 cassette (ThermoFisher Scientific, 87730), Adenosine-50-triphosphate (Sigma-Aldrich, A2383) (ATP), Amicon Ultra 30K centrifugal filter (Millipore, UFC803096), Ammonium chloride (NH4Cl), anti-Flag M2 affinity gel (Sigma-Aldrich, A2220), Any kD Mini-PROTEAN TGX Precast Protein Gels 15-well (for coomassie stains) Bio-Rad, 4569036, astemizole (Sigma-Aldrich, A2861), bafilomycin A1 (AH diagnostics, BML-CM110) (BafA1), BalanCD HEK293 Feed (Irvine Scientific, 91166), BalanCD HEK293 Liquid (Irvine Scientific, 91165), blasticidine S (InvivoGen, ant-bl-1), Citrate Buffer pH 3.0 (TekNova, Q2445), Synthesized:Article Title: Expression of a RAS Degrader via Synthetic Nanocarrier-Mediated mRNA Delivery Reduces Pancreatic Tumors. Article Snippet: Therapeutic gene expression can address many of the challenges associated with the controlled delivery of intracellularly active biologics, such as enzymes that degrade RAS for the treatment of RAS-driven cancers.. Here, we demonstrate that an optimized synthetic nonviral gene delivery platform composed of poly(ethylene glycol)-b-poly(propylene sulfide) (PEG−PPS) can block copolymers conjugated to a dendritic cationic peptide (PPDP2) for nontoxic delivery and therapeutic expression of mRNA within human pancreatic cancer cells and tumors.. The naturally occurring bacterial enzyme RAS/RAP1-specific endopeptidase (RRSP) is a potent RAS degrader that specifically targets all RAS isoforms. Article Title: Don't shake it! Mechanical stress testing of mRNA-lipid nanoparticles. Article Snippet: PolyA (ABP Biosciences, Virginia, USA) or Article Title: TECPR1 is activated by damage-induced sphingomyelin exposure to mediate noncanonical autophagy. Article Snippet: Other reagents used were 10k MWCO Slide-A-Lyzer G2 cassette (ThermoFisher Scientific, 87730), Adenosine-50-triphosphate (Sigma-Aldrich, A2383) (ATP), Amicon Ultra 30K centrifugal filter (Millipore, UFC803096), Ammonium chloride (NH4Cl), anti-Flag M2 affinity gel (Sigma-Aldrich, A2220), Any kD Mini-PROTEAN TGX Precast Protein Gels 15-well (for coomassie stains) Bio-Rad, 4569036, astemizole (Sigma-Aldrich, A2861), bafilomycin A1 (AH diagnostics, BML-CM110) (BafA1), BalanCD HEK293 Feed (Irvine Scientific, 91166), BalanCD HEK293 Liquid (Irvine Scientific, 91165), blasticidine S (InvivoGen, ant-bl-1), Citrate Buffer pH 3.0 (TekNova, Q2445), |
